{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:30:01Z","timestamp":1793896201188,"version":"4.8.0"},"reference-count":39,"publisher":"Informa UK Limited","issue":"36","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.2217\/fon-2022-0976","type":"journal-article","created":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T14:18:31Z","timestamp":1668521911000},"page":"3961-3969","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":29,"title":["BRUIN MCL-321: Phase III Study of Pirtobrutinib Versus Investigator Choice of BTK Inhibitor in BTK Inhibitor Naive Mantle Cell Lymphoma"],"prefix":"10.1080","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6631-9749","authenticated-orcid":false,"given":"Toby A","family":"Eyre","sequence":"first","affiliation":[{"name":"Oxford University Hospitals NHS Foundation Trust,Churchill Cancer Center,\rOxford,\rUK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirav N","family":"Shah","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin,\rMilwaukee,\rWI\r53226,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[{"name":"Department of Medicine III,LMU University Hospital,\rMunich,\rGermany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Jurczak","sequence":"additional","affiliation":[{"name":"Maria Sklodowska-Curie National Research Institute of Oncology,\rKrakow,\rPoland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yucai","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Hematology,Mayo Clinic,\rRochester,\rMN 55902,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan Y","family":"Cheah","sequence":"additional","affiliation":[{"name":"Linear Clinical Research & Sir Charles Gairdner Hospital,\rPerth,\rAustralia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqin","family":"Song","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education),Peking University Cancer Hospital & Institute,\rBeijing,\rChina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitul","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Virginia Cancer Specialists,\rFairfax,\rVA\r22031,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Chay","sequence":"additional","affiliation":[{"name":"Messino Cancer Centers,\rAsheville,\rNC 28806,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Sharman","sequence":"additional","affiliation":[{"name":"Willamette Valley Cancer Institute & Research Center,US Oncology Research,\rEugene,\rOR\r97401,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J","family":"Andorsky","sequence":"additional","affiliation":[{"name":"Rocky Mountain Cancer Centers,US Oncology Research,\rBoulder,\rCO\r80303,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah M","family":"Messersmith","sequence":"additional","affiliation":[{"name":"Eli Lilly & Company,\rIndianapolis,\rIN\r46225,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S","family":"Ruppert","sequence":"additional","affiliation":[{"name":"Eli Lilly & Company,\rIndianapolis,\rIN\r46225,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie A","family":"Muthig","sequence":"additional","affiliation":[{"name":"Eli Lilly & Company,\rIndianapolis,\rIN\r46225,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Ito","sequence":"additional","affiliation":[{"name":"Eli Lilly & Company,\rIndianapolis,\rIN\r46225,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L","family":"Wang","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center,\rHouston,\rTX\r77030,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,11,15]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2202672"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1403602"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx223"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.133"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.8435"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24094"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn045"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14241"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt070"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0209-5"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn656"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00559-8"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.7977"},{"key":"e_1_3_6_17_1","unstructured":"US Food and Drug Administration . Revlimid (lenalidomide) (2005). www.Accessdata.Fda.Gov\/Drugsatfda_Docs\/Label\/2005\/021880lbl.Pdf"},{"key":"e_1_3_6_18_1","unstructured":"US Food and Drug Administration . Velcade (bortezomib) (2005). www.Accessdata.Fda.Gov\/Drugsatfda_Docs\/Label\/2005\/021602s006lbl.Pdf"},{"key":"e_1_3_6_19_1","unstructured":"European Medicines Agency . Torisel (temsirolimus) (2017). www.ema.europa.eu\/en\/documents\/overview\/torisel-epar-summary-public_en.pdf"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2225"},{"key":"e_1_3_6_21_1","unstructured":"European Medicines Agency . Imbruvica (ibrutinib) (2020). www.ema.europa.eu\/en\/documents\/overview\/imbruvica-epar-medicine-overview_en.pdf"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000712"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001160"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33108-2"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-117956"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16922"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.182907"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.147900"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-604272"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.247"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215637"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509981"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016953"},{"key":"e_1_3_6_34_1","volume-title":"European Hematology Association Congress.","author":"Hillmen P","year":"2021","unstructured":"Hillmen P , EichhorstB, BrownJRet al. First interim analysis of ALPINE study: results of a phase III randomized study of zanubrutinib vs ibrutinib in patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma. Presented at: European Hematology Association Congress. (June 9\u201317, 2021)."},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01210"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2201817"},{"key":"e_1_3_6_37_1","first-page":"2","volume-title":"Annual Meeting of the Society of Hematologic Oncology (SOHO).","author":"Brandhuber B","year":"2018","unstructured":"Brandhuber B , GomezE, SmithSet al. LOXO-305, a next generation reversible BTK inhibitor, for overcoming acquired resistance to irreversible BTK inhibitors. Presented at: Annual Meeting of the Society of Hematologic Oncology (SOHO).TX, USA, 2\u201315 (2018)."},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00224-5"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-149138"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-145920"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2022-0976","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:46:30Z","timestamp":1719125190000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2022-0976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":39,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.2217\/fon-2022-0976"],"URL":"https:\/\/doi.org\/10.2217\/fon-2022-0976","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-09-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}